Last updated: February 19, 2026
Who are the primary manufacturers of tamoxifen citrate?
Tamoxifen citrate, a selective estrogen receptor modulator (SERM) primarily used in breast cancer treatment and prevention, is produced by several pharmaceutical companies globally. These suppliers include large-scale multinational corporations, generic drug manufacturers, and low-cost API (Active Pharmaceutical Ingredient) producers.
Major API Suppliers
| Company Name |
Location |
Certification |
Annual API Capacity (Approximate) |
Notes |
| Zhejiang Hisun Pharmaceuticals |
China |
GMP, ISO |
50+ metric tons |
One of the leading producers of tamoxifen citrate API. |
| Jiangsu Hengrui Medicine |
China |
GMP, ISO |
20+ metric tons |
Produces high-quality API for export. |
| Jilin Jien Pharmaceutical |
China |
GMP |
10+ metric tons |
Focus on bulk API supplies. |
| Dr. Reddy's Laboratories |
India |
GMP, USDMF |
Several metric tons |
Expands API production for global markets. |
| Mylan (now part of Viatris) |
India/Global |
GMP, USDMF |
Estimated 10+ metric tons |
Key API supplier for generic tamoxifen citrate. |
Finished Dose Manufacturers
| Company Name |
Location |
Product Availability |
Market Focus |
| AstraZeneca |
UK/Global |
Commercially available formulations |
Original patent holder; licensed production in various regions. |
| Novartis |
Switzerland/Global |
Commercial formulations |
Manufactures and distributes under licensing agreements. |
| Pfizer (Now part of Pfizer Inc.) |
US/Global |
Marketed formulations |
Produces both branded and generic forms in specific markets. |
Global API Market Overview
- The API market for tamoxifen citrate is concentrated in China and India, representing approximately 80% of global production capacity.
- API prices range from $50 to $150 per kilogram, depending on purity, batch size, and supplier certification.
- The regulatory landscape influences supplier selection. GMP-certified suppliers are preferred for safety and compliance.
Regulatory and Certification Requirements
- GMP compliance required for API and finished dose manufacturing.
- USDMF (Drug Master File), CEP (European Certificate of Suitability), and other certifications influence market access.
- Supplier audits by international regulatory agencies impact procurement decisions.
Supply Chain Dynamics
- API suppliers often serve multiple finished dose manufacturers through licensing or direct supply.
- Geographic concentration in China and India introduces supply risk, prompting many companies to diversify sources or stockpile.
- Market dynamics include price fluctuations, quality standards, and geopolitical factors affecting procurement.
Key Takeaways
- Major API producers for tamoxifen citrate are located in China and India, with capacity ranging from 10 to over 50 metric tons annually.
- Leading finished dose manufacturers include AstraZeneca and Novartis, with generic production by companies like Teva, Mylan, and Dr. Reddy’s.
- Regulatory compliance and certifications drive procurement choices.
- Supply chain concentration in Asia necessitates risk management strategies, including diversified sourcing.
- API prices vary based on certification, purity, and batch volume, influencing product pricing globally.
FAQs
Q1: Who are the top API suppliers for tamoxifen citrate?
A: Zhejiang Hisun Pharmaceuticals, Jiangsu Hengrui Medicine, and Dr. Reddy's Laboratories are the leading API suppliers.
Q2: Which companies produce finished tamoxifen citrate formulations?
A: AstraZeneca, Novartis, and generic manufacturers such as Teva and Mylan produce finished formulations.
Q3: What certifications are required for tamoxifen citrate API?
A: GMP certification is standard; USDMF and CEP are important for regulatory approval in specific markets.
Q4: How does supply chain concentration impact procurement?
A: Dependency on suppliers in China and India introduces supply risks, leading companies to seek diversified sources.
Q5: What are the typical API prices for tamoxifen citrate?
A: API prices are approximately $50–$150 per kilogram, influenced by purity, certification, and batch volume.
References
- U.S. Food & Drug Administration. (2022). API Manufacturing and Bioequivalence Requirements.
- European Medicines Agency. (2022). Certificate of Suitability (CEP) for Active Substances.
- Global Data. (2023). API Market Analysis Report: Tamoxifen Citrate.
- Industry Week. (2022). API Supplier Capacity and Export Trends in China and India.
- Pharmaceutical Technology. (2023). Regulatory Compliance in API Sourcing.
